Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread or cannot be treated with a combination of treatments) confirmed by a lab test on a tissue or blood sample
- People whose lung cancer has a specific genetic change called an ALK rearrangement, confirmed through testing of tissue or blood
- People who have not previously received systemic (whole-body) cancer treatment for this lung cancer — though chemotherapy given before or after surgery is allowed if it was completed at least 12 months before joining the trial; prior treatment with ALK-targeting drugs (such as alectinib) is not allowed under any circumstances
- People who have at least one measurable area of cancer that can be tracked using standard imaging criteria
- People who can provide a tumour tissue sample taken before the trial begins
Who may not be able to join:
- People whose cancer has a known genetic driver other than the ALK rearrangement
- People with a known allergy or sensitivity to the ingredients in either of the study drugs (neladalkib or alectinib)
- People who have recently received or are currently receiving radiation therapy within timeframes specified by the trial protocol (confirm with trial site)
- People who have had major surgery within 4 weeks before joining the trial
- People who have an active, uncontrolled infection that requires treatment with systemic (whole-body) medicines
- People with known active tuberculosis, or active Hepatitis B or Hepatitis C infection
- People with a specific heart rhythm measurement (QTcF) above 470 milliseconds on repeated checks, which may indicate a heart electrical problem
- People with a significant heart or cardiovascular condition
- People with brain metastases (cancer that has spread to the brain) that are causing worsening neurological symptoms or require increasing doses of steroid medicines to manage
- People who have had another active cancer requiring treatment within the 2 years before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kelly Curtis, MD, Nuvalent Inc.
Phone: 857-357-7000
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-free survival (PFS) per blinded independent central review (BICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.